High-Intensity Statins May Confer a Survival Advantage

High-intensity statins were associated with a significant survival advantage compared with moderate-intensity statins, even among older adults.
High-intensity statins were associated with a significant survival advantage compared with moderate-intensity statins, even among older adults.

HealthDay News — There is a graded association between intensity of statin therapy and mortality for patients with established atherosclerotic cardiovascular disease, according to research published online in JAMA Cardiology.

The study included 499,598 men and 10,168 women with atherosclerotic cardiovascular disease, all of whom were military veterans. Their average age was 68.5 years at the start of the study. Of the participants, 29.6% were receiving high-dose statin therapy, 45.6% were on moderate-dose statins, 6.7% were taking low-dose statins, and 18.2% weren't taking statins at all.

After adjustment for propensity to receive high-intensity statins, the hazard ratio for mortality was 0.91 for those receiving high- vs moderate-intensity statins. The hazard ratio was also 0.91 for patients aged 76 to 84 years.

"High-intensity statins were associated with a small but significant survival advantage compared with moderate-intensity statins, even among older adults," the authors write. "Maximal doses of high-intensity statins were associated with a further survival benefit."

Reference

  1. Rodriguez F, Maron DJ, Knowles JW, et al. Association Between Intensity of Statin Therapy and Mortality in Patients With Atherosclerotic Cardiovascular Disease. JAMA Cardiol. 9 November 2016. doi:10.1001/jamacardio.2016.4052

Loading links....

Related Slideshows

You must be a registered member of Renal and Urology News to post a comment.

Newsletter Signup